3 results
Approved WMOWill not start
The primary objective of this study is to further evaluate the safety and tolerability of pegaptanib sodium in subjects with DME.
Approved WMOCompleted
*To demonstrate comparability of the ORR in patients with previously untreated, advanced stage FL who receive GP2013-CVP combination treatment to patients who receive MabThera®-CVP treatment. ORR will be determined during the combination treatment…
Approved WMOPending
Primary objectiveTo compare the effect on psoriasis symptoms of an adjustable brodalumab dosage regimen to standard brodalumab treatment in subjects with moderate-to-severe psoriasis and a body weight >=120 kg.Secondary objectives:To evaluate…